Rep. Gilbert Cisneros Buys BridgeBio Pharma (BBIO) Stock
Cisneros disclosed a purchase of BridgeBio Pharma shares valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros bought between $1,001 and $15,000 of BridgeBio Pharma, Inc. ($BBIO) stock on May 11, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $BBIO is up 1.0% after 1 week, up 4.2% after 1 month and up 2.6% to date (from the $64.68 close on May 11, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| BridgeBio Pharma, Inc. ($BBIO) | Buy | May 11, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BBIO
BridgeBio Pharma, Inc.
Key Points
- Rep. Gilbert Cisneros bought BridgeBio Pharma shares, valued between $1,001 and $15,000, as disclosed on June 9, 2026.
- BridgeBio Pharma, trading at $67.14, has a market cap of $13.08 billion and a forward P/E of 134.9.
- Insiders and analysts show active interest, with CEO Neil Kumar selling shares and analysts maintaining 'buy' ratings.
Get $BBIO trade alerts by text
We text you when insiders, Congress or big funds trade $BBIO. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated BridgeBio Pharma, Inc. alert may contain errors. Disclosures
On June 9, 2026, Rep. Gilbert Cisneros disclosed a purchase of BridgeBio Pharma, Inc. shares, valued between $1,001 and $15,000. This transaction was reported as part of the STOCK Act requirements, which mandate the disclosure of stock trades by members of Congress.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
BridgeBio Pharma, Inc. Stock Down 0.1%
Shares of NasdaqGS:BBIO traded at $67.14 recently. BridgeBio Pharma, Inc. is a biotechnology company based in Palo Alto, California, with a market capitalization of about $13.08 billion. The company has a forward P/E ratio of 134.9 and a beta of 0.975, indicating moderate volatility. Over the past year, the stock has ranged from $38.58 to $84.94, with recent moving averages of $70.28 (50-day) and $67.14 (200-day).
Insider Buying and Selling at BridgeBio Pharma, Inc.
Insider activity at BridgeBio Pharma has been notable. CEO Neil Kumar sold 40,000 shares at an average price of $67.88 on June 5, 2026, as part of a planned sale. Earlier, on May 16, 2026, Kumar bought 71,215 shares, showing active involvement in the company's stock. Additionally, President and CFO Thomas Trimarchi sold 22,781 shares at $66.13 on May 16, 2026.
Analysts Set New Price Targets
BridgeBio Pharma has caught the attention of analysts. On June 3, 2026, Canaccord Genuity initiated coverage with a 'buy' rating and a $104 price target. HC Wainwright & Co. maintained a 'buy' rating with a $110 target on May 11. The consensus among 23 analysts is a 'strong buy,' with an average price target of $102.71.
About BridgeBio Pharma
BridgeBio Pharma, Inc., founded in 2015, is a biopharmaceutical company focused on developing treatments for genetic diseases. The company, headquartered in Palo Alto, California, is led by CEO Dr. Neil Kumar and employs 834 people. BridgeBio develops a range of medicines, including those for cardiomyopathy, molybdenum cofactor deficiency, and genetic bone disorders.
Bottom Line
Rep. Gilbert Cisneros's purchase of BridgeBio Pharma shares adds to the interest in the company from both insiders and analysts. While the 13F filings are backward-looking, this disclosure highlights ongoing interest in the biotech sector. Investors often track such moves for insights into potential trends and market sentiment.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $BBIO (May 11, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts